Clinical Trial Update: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating UX007 (triheptanoin) in participants with long-chain fatty acid oxidation disorders (LC-FAOD) has completed, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carnitine Palmitoyltransferase Deficiency
• Long-chain Fatty Acid Oxidation Disorders
• Longchain 3-hydroxy-acyl-coa Dehydrogenase Deficiency
• Trifunctional Protein Deficiency
• Very Long-chain Acyl-coa Dehydrogenase Deficiency

Drugs mentioned

• UX007 (triheptanoin)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2021-02-11